BACKGROUND: Since 2008, orally administered @entity1169 has rapidly gained acceptance as the preferred therapy for haemangiomas, and is usually initiated by ophthalmologists, dermatologists or plastic surgeons who do not routinely use @entity1169 for any other indication. During the initial years when experience was limited, most healthcare professionals justifiably adopted a cautious approach when initiating and monitoring treatment. A consensus recommendation from the American Society of Dermatologists suggests routine observation, monitoring and cardiology assessments prior to @entity1169 initiation. AIM: This study aims to analyse treatment initiation in a large tertiary @entity1 's hospital and investigate the value of pretreatment testing in predicting commonly seen adverse reactions of @entity1169 . METHOD: 104 eligible @entity1 treated between January 2009 and July 2012 were included. All @entity1 underwent pretesting either with protocol A (administration of test dose with routine observations) or protocol B (cardiology clinic assessment, including two-dimensional echocardiography without test dose). RESULTS: 38.5% (40/104) of @entity1 developed adverse reactions during treatment; however, there were no severe or life-threatening reactions. Protocol A has a sensitivity of 0 (95% CI 0 to 0.17) and specificity of 0.95 (95% CI 0.83 to 0.99). Protocol B has a sensitivity of 0.07 (95% CI 0 to 0.34) and specificity of 0.86 (95% CI 0.63 to 0.96). CONCLUSIONS: The predictive values of both protocols for the commonly observed adverse reactions are low. In this series, there is no evidence to suggest that routine pretreatment testing before @entity1169 initiation is of any value in otherwise healthy @entity1 .

Predicting complications with pretreatment testing in infantile haemangioma treated with oral XXXX .

@entity1169 :: ('MESH:D011433', 'Chemical') :: ['propranolol'] @entity1 :: ('9606', 'Species') :: ['patients', 'children']
@entity1169 :: (MESH:D011433,Chemical) :: ['propranolol']
